Momordica Charantia lectin, a type II ribosome inactivating protein, exhibits antitumor activity toward human nasopharyngeal carcinoma cells in Vitro and in Vivo

Cancer Prevention Research

Volumn 5, Issue 1, 2012, Pages 109-121

  Fang, Evandro Fei ^a   Zhang, Chris Zhi Yi ^b   Ng, Tzi Bun ^a   Wong, Jack Ho ^a   Pan, Wen Liang ^a   Ye, Xiu Juan ^a   Chan, Yau Sang ^a   Fong, Wing Ping ^c  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN D1; CYTOCHROME C; LECTIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; MOMORDICA CHARANTIA EXTRACT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE; RETINOBLASTOMA BINDING PROTEIN; RIBOSOME INACTIVATING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA FRAGMENTATION; DRUG RESEARCH; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LETHALITY; MOMORDICA CHARANTIA; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; DNA FRAGMENTATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; LECTINS; MAP KINASE SIGNALING SYSTEM; MEMBRANE POTENTIALS; MICE; MICE, NUDE; MOMORDICA CHARANTIA; NASOPHARYNGEAL NEOPLASMS; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PLANT EXTRACTS; REMISSION INDUCTION; RIBOSOME INACTIVATING PROTEINS;

EID: 84862907973     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0203     Document Type: Article

References (56)

1. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005;365:2041-54. (Pubitemid 40812341)
2. McDermott AL, Dutt SN, Watkinson JC. The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci 2001;26:82-92. (Pubitemid 32368223)
3. Bei JX, Li Y, Jia WH, Feng BJ, Zhou G, Chen LZ, et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet 2010;42:599-603.
4. Nicholls JM. Nasopharyngeal carcinoma: classification and histological appearance. Adv Anat Path 1997;4:71-84.
5. Lu SJ, Day NE, Degos L, Lepage V, Wang PC, Chan SH, et al. Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature 1990;346:470-1. (Pubitemid 120005926)
6. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002;12:421-9. (Pubitemid 35370755)
7. Hu ZY, Zhu XF, Zhong ZD, Sun J, Wang J, Yang D, et al. ApoG2, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts. Int J Cancer 2008;123:2418-29.
8. Fang EF, Ng TB. Bitter gourd (Momordica charantia) is a cornucopia of health: A review of its credited antidiabetic, anti-HIV, and antitumor properties. Curr Mol Med 2011;11:417-36.
9. Jilka C, Strifler B, Fortner GW, Hays EF, Takemoto DJ. In vivo antitumor activity of the bitter melon (Momordica charantia). Cancer Res 1983;43:5151-5. (Pubitemid 14227492)
10. Ray RB, Raychoudhuri A, Steele R, Nerurkar P. Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res 2010;70:1925-31.
11. Xiong SD, Yu K, Liu XH, Yin LH, Kirschenbaum A, Yao S, et al. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int J Cancer 2009;125:774-82.
12. Chandran T, Sharma A, Vijayan M. Crystallization and preliminary X-ray studies of a galactose-specific lectin from the seeds of bitter gourd (Momordica charantia). Acta Crystallogr Sect F Struct Biol Cryst Commun 2010;66:1037-40.
13. Barbieri L, Zamboni M, Lorenzoni E, Montanaro L, Sperti S, Stirpe F. Inhibition of protein synthesis in vitro by proteins from the seeds of Momordica charantia (bitter pear melon). Biochem J 1980;186:443-52. (Pubitemid 10097485)
14. Fang EF, Lin P, Wong JH, Tsao SW, Ng TB. A lectin with anti-HIV-1 reverse transcriptase, antitumor, and nitric oxide inducing activities from seeds of Phaseolus vulgaris cv. extralong autumn purple bean. J Agric Food Chem 2010;58:2221-9.
15. Fang EF, Pan WL, Wong JH, Chan YS, Ye XJ, Ng TB. A new Phaseolus vulgaris lectin induces selective toxicity on human liver carcinoma Hep G2 cells. Arch Toxicol 2011 Mar 29. [Epub ahead of print].
16. Hu ZY, Sun J, Zhu XF, Yang D, Zeng YX. ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway. J Transl Med 2009;7:74.
17. Cossarizza A, Baccarani-Contri M, Kalashnikova G, Franceschi C. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′- tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem Biophys Res Commun 1993;197:40-5. (Pubitemid 23358874)
18. Zhang CZ, Zhang HT, Chen GG, Lai PB. Trichostatin A sensitizes HBx-expressing liver cancer cells to etoposide treatment. Apoptosis 2011;16:683-95.
19. Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, Dent P, et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 2010;115:4478-87.
20. Ng TB, Wong CM, Li WW, Yeung HW. Isolation and characterization of a galactose binding lectin with insulinomimetic activities. From the seeds of the bitter gourdMomordica charantia (Family Cucurbitaceae). Int J Pept Protein Res 1986;28:163-72. (Pubitemid 16012937)
21. Mazumder T, Gaur N, Surolia A. The physicochemical properties of the galactose-specific lectin from Momordica charantia. Eur J Biochem 1981;113:463-70.
22. Khan MI, Mazumder T, Pain D, Gaur N, Surolia A. Binding of 4- methylumbelliferyl beta-D-galactopyranoside to Momordica charantia lectin: fluorescence-quenching studies. Eur J Biochem 1981;113:471-6.
23. Tanaka H, Toyama J, Akashi R. Molecular characterization of a galactose- binding lectin from Momordica charantia seeds and its expression in tobacco cells. Asian J Plant Sci 2009;8:544-50.
24. Kelley LA, Sternberg MJ. Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc 2009;4:363-71.
25. Bae MA, Rhee H, Song BJ. Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. Toxicol Lett 2003;139:67-75. (Pubitemid 36197848)
26. Ye M, Luo X, Li L, Shi Y, Tan M, Weng X, et al. Grifolin, a potential antitumor natural product from the mushroom Albatrellus confluens, induces cell-cycle arrest in G1 phase via the ERK1/2 pathway. Cancer Lett 2007;258:199-207. (Pubitemid 350101018)
27. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 2007; 10:13-29. (Pubitemid 46636381)
28. Chang L, Karin M. MammalianMAPkinase signalling cascades. Nature 2001;410:37-40.
29. Chen J, Rusnak M, Luedtke RR, Sidhu A. D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. J Biol Chem 2004;279:39317-30. (Pubitemid 39258194)
30. Li F, Mei Y, Wang Y, Chen C, Tu J, Xiao B, et al. Trichosanthin inhibits antigen-specific T cell expansion through nitric oxide-mediated apoptosis pathway. Cell Immunol 2005;234:23-30. (Pubitemid 41140388)
31. Hassoun EA, Wang X. Time- and concentration-dependent production of superoxide anion, nitric oxide, DNA damage and cellular death by ricin in the J774A.1 macrophage cells. J Biochem Mol Toxicol 1999;13:179-85. (Pubitemid 129705390)
32. Papapetropoulos A, Desai KM, Rudic RD, Mayer B, Zhang R, Ruiz- Torres MP, et al. Nitric oxide synthase inhibitors attenuate transforming- growth-factor-beta 1-stimulated capillary organization in vitro. Am J Pathol 1997;150:1835-44. (Pubitemid 27193829)
33. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004;5:897-907. (Pubitemid 39486541)
34. Jiang X, Wang X. Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1. J Biol Chem 2000;275:31199-203.
35. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9- dependent manner. J Cell Biol 1999;144:281-92. (Pubitemid 29066031)
36. Comoli P, De Palma R, Siena S, Nocera A, Basso S, Del Galdo F, et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol 2004;15:113-7. (Pubitemid 38139611)
37. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 2010;33:983-90.
38. Xia H, Cheung WK, Sze J, Lu G, Jiang S, Yao H, et al. miR-200a regulates epithelial-mesenchymal to stem-like transition via ZEB2 and beta-catenin signaling. J Biol Chem 2010;285:36995-7004.
39. Huang TT, Lin HC, Chen CC, Lu CC, Wei CF, Wu TS, et al. Resveratrol induces apoptosis of human nasopharyngeal carcinoma cells via activation of multiple apoptotic pathways. J Cell Physiol 2011;226:720-8.
40. Feng Z, Xu S, Liu M, Zeng YX, Kang T. Chk1 inhibitor Go6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo. Cancer Lett 2010;297:190-7.
41. Lui VW, Lau CP, Ho K, Ng MH, Cheng SH, Tsao SW, et al. Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. Invest New Drugs 2011;29:1241-52.
42. Seto M, Umemoto N, Saito M, Masuho Y, Hara T, Takahashi T. Monoclonal anti-MM46 antibody:ricin A chain conjugate: in vitro and in vivo antitumor activity. Cancer Res 1982;42:5209-15. (Pubitemid 13223170)
43. Sharon N, Lis H. History of lectins: from hemagglutinins to biological recognition molecules. Glycobiology 2004;14:53R-62R. (Pubitemid 39430025)
44. Sahara S, Aoto M, Eguchi Y, Imamoto N, Yoneda Y, Tsujimoto Y. Acinus is a caspase-3-activated protein required for apoptotic chromatin condensation. Nature 1999;401:168-73. (Pubitemid 29436320)
45. Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 2004;287:C281-91. (Pubitemid 38955218)
46. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, et al. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 1997;272:22199-206. (Pubitemid 27382850)
47. Vaziri C, Stice L, Faller DV. Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ 1998;9:465-74. (Pubitemid 28345871)
48. Yang H, Zhao R, Lee MH. 14-3-3sigma, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma. Mol Cancer Ther 2006;5: 253-60.
49. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109. (Pubitemid 39331023)
50. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000;14:262-70. (Pubitemid 30095381)
51. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, aBcl2 interacting protein,mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94:481-90. (Pubitemid 28391864)
52. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003;63:3637-45. (Pubitemid 36793047)
53. Deng X, Gao F, Flagg T, May WS Jr. Mono- and multisite phosphorylation enhances Bcl20s antiapoptotic function and inhibition of cell cycle entry functions. Proc Natl Acad Sci U S A 2004;101:153-8. (Pubitemid 38084219)
54. Thorpe PE, Wallace PM, Knowles PP, Relf MG, Brown AN, Watson GJ, et al. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res 1988;48:6396-403.
55. Fang EF, Ng TB. Ribonucleases of different origins with a wide spectrum of medicinal applications. Biochim Biophys Acta-Rev Cancer 2011;1815:65-74.
56. Huang PL, Sun Y, Chen HC, Kung HF, Lee-Huang S. Proteolytic fragments of anti-HIV and anti-tumor proteins MAP30 and GAP31 are biologically active. Biochem Biophys Res Commun 1999;262:615-23. (Pubitemid 29443706)